vs
CEMTREX INC（CETX）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是CEMTREX INC的1.9倍（$30.3M vs $16.1M），CEMTREX INC净利率更高（-127.4% vs -221.3%，领先93.9%），REGENXBIO Inc.同比增速更快（43.0% vs 17.4%），CEMTREX INC自由现金流更多（$-1.1M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs -3.0%）
Cemtrex Inc是一家多元化工业科技企业，主营物联网工业自动化解决方案、环境监测系统及数字办公工具，核心客户主要来自北美、欧洲的制造、工业及商业领域。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
CETX vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.9倍
$16.1M
营收增速更快
RGNX
高出25.6%
17.4%
净利率更高
CETX
高出93.9%
-221.3%
自由现金流更多
CETX
多$51.7M
$-52.8M
两年增速更快
RGNX
近两年复合增速
-3.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $16.1M | $30.3M |
| 净利润 | $-20.6M | $-67.1M |
| 毛利率 | 34.8% | — |
| 营业利润率 | -17.4% | -190.0% |
| 净利率 | -127.4% | -221.3% |
| 营收同比 | 17.4% | 43.0% |
| 净利润同比 | 28.5% | -31.2% |
| 每股收益（稀释后） | — | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CETXRGNX
| Q4 25 | $16.1M | $30.3M | ||
| Q3 25 | $18.5M | $29.7M | ||
| Q2 25 | $17.0M | $21.4M | ||
| Q1 25 | $27.3M | $89.0M | ||
| Q4 24 | $13.7M | $21.2M | ||
| Q3 24 | $18.1M | $24.2M | ||
| Q2 24 | $14.7M | $22.3M | ||
| Q1 24 | $17.2M | $15.6M |
净利润CETXRGNX
| Q4 25 | $-20.6M | $-67.1M | ||
| Q3 25 | $-3.4M | $-61.9M | ||
| Q2 25 | $-4.5M | $-70.9M | ||
| Q1 25 | $8.4M | $6.1M | ||
| Q4 24 | $-28.8M | $-51.2M | ||
| Q3 24 | $4.4M | $-59.6M | ||
| Q2 24 | $-9.0M | $-53.0M | ||
| Q1 24 | $-1.5M | $-63.3M |
毛利率CETXRGNX
| Q4 25 | 34.8% | — | ||
| Q3 25 | 38.0% | — | ||
| Q2 25 | 43.4% | — | ||
| Q1 25 | 44.6% | — | ||
| Q4 24 | 41.5% | 70.2% | ||
| Q3 24 | 41.8% | 48.8% | ||
| Q2 24 | 40.0% | 52.5% | ||
| Q1 24 | 40.4% | 72.6% |
营业利润率CETXRGNX
| Q4 25 | -17.4% | -190.0% | ||
| Q3 25 | -6.4% | -176.3% | ||
| Q2 25 | -3.8% | -296.3% | ||
| Q1 25 | 16.9% | 13.6% | ||
| Q4 24 | -16.6% | -242.1% | ||
| Q3 24 | -1.8% | -256.6% | ||
| Q2 24 | -21.6% | -251.3% | ||
| Q1 24 | -6.0% | -408.8% |
净利率CETXRGNX
| Q4 25 | -127.4% | -221.3% | ||
| Q3 25 | -18.1% | -208.3% | ||
| Q2 25 | -26.8% | -331.8% | ||
| Q1 25 | 30.8% | 6.8% | ||
| Q4 24 | -209.3% | -241.3% | ||
| Q3 24 | 24.1% | -246.3% | ||
| Q2 24 | -61.2% | -237.7% | ||
| Q1 24 | -8.6% | -405.4% |
每股收益（稀释后）CETXRGNX
| Q4 25 | — | $-1.30 | ||
| Q3 25 | — | $-1.20 | ||
| Q2 25 | — | $-1.38 | ||
| Q1 25 | — | $0.12 | ||
| Q4 24 | — | $-0.99 | ||
| Q3 24 | — | $-1.17 | ||
| Q2 24 | — | $-1.05 | ||
| Q1 24 | — | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $20.5M | $230.1M |
| 总债务越低越好 | $12.8M | — |
| 股东权益账面价值 | $29.1M | $102.7M |
| 总资产 | $60.3M | $453.0M |
| 负债/权益比越低杠杆越低 | 0.44× | — |
8季度趋势，按日历期对齐
现金及短期投资CETXRGNX
| Q4 25 | $20.5M | $230.1M | ||
| Q3 25 | $5.0M | $274.2M | ||
| Q2 25 | $7.0M | $323.3M | ||
| Q1 25 | $4.5M | $267.9M | ||
| Q4 24 | $4.2M | $234.7M | ||
| Q3 24 | $3.9M | $255.5M | ||
| Q2 24 | $6.5M | $290.4M | ||
| Q1 24 | $2.9M | $338.7M |
总债务CETXRGNX
| Q4 25 | $12.8M | — | ||
| Q3 25 | $13.5M | — | ||
| Q2 25 | $18.3M | — | ||
| Q1 25 | $18.9M | — | ||
| Q4 24 | $18.7M | — | ||
| Q3 24 | $18.0M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $21.6M | — |
股东权益CETXRGNX
| Q4 25 | $29.1M | $102.7M | ||
| Q3 25 | $8.7M | $161.5M | ||
| Q2 25 | $3.6M | $213.7M | ||
| Q1 25 | $6.4M | $274.2M | ||
| Q4 24 | $-1.6M | $259.7M | ||
| Q3 24 | $4.7M | $301.4M | ||
| Q2 24 | $48.0K | $348.3M | ||
| Q1 24 | $4.7M | $390.7M |
总资产CETXRGNX
| Q4 25 | $60.3M | $453.0M | ||
| Q3 25 | $47.8M | $525.2M | ||
| Q2 25 | $47.0M | $581.0M | ||
| Q1 25 | $46.2M | $490.9M | ||
| Q4 24 | $46.7M | $466.0M | ||
| Q3 24 | $44.1M | $519.1M | ||
| Q2 24 | $43.8M | $569.4M | ||
| Q1 24 | $47.2M | $629.2M |
负债/权益比CETXRGNX
| Q4 25 | 0.44× | — | ||
| Q3 25 | 1.55× | — | ||
| Q2 25 | 5.07× | — | ||
| Q1 25 | 2.94× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.82× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 4.60× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-891.9K | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $-1.1M | $-52.8M |
| 自由现金流率自由现金流/营收 | -6.7% | -174.0% |
| 资本支出强度资本支出/营收 | 1.1% | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-721.5K | $-126.4M |
8季度趋势，按日历期对齐
经营现金流CETXRGNX
| Q4 25 | $-891.9K | $-52.3M | ||
| Q3 25 | $-3.3M | $-56.0M | ||
| Q2 25 | $1.8M | $-49.3M | ||
| Q1 25 | $2.8M | $33.6M | ||
| Q4 24 | $-1.2M | $-31.6M | ||
| Q3 24 | $-1.9M | $-40.5M | ||
| Q2 24 | $675.8K | $-45.5M | ||
| Q1 24 | $386.8K | $-55.5M |
自由现金流CETXRGNX
| Q4 25 | $-1.1M | $-52.8M | ||
| Q3 25 | $-3.7M | $-56.5M | ||
| Q2 25 | $1.7M | $-49.7M | ||
| Q1 25 | $2.4M | $32.6M | ||
| Q4 24 | $-2.1M | $-32.7M | ||
| Q3 24 | $-2.7M | $-40.9M | ||
| Q2 24 | $601.7K | $-46.0M | ||
| Q1 24 | $322.2K | $-56.0M |
自由现金流率CETXRGNX
| Q4 25 | -6.7% | -174.0% | ||
| Q3 25 | -20.2% | -189.9% | ||
| Q2 25 | 10.2% | -232.8% | ||
| Q1 25 | 8.7% | 36.6% | ||
| Q4 24 | -15.5% | -154.2% | ||
| Q3 24 | -15.1% | -168.9% | ||
| Q2 24 | 4.1% | -206.2% | ||
| Q1 24 | 1.9% | -358.5% |
资本支出强度CETXRGNX
| Q4 25 | 1.1% | 1.7% | ||
| Q3 25 | 2.7% | 1.7% | ||
| Q2 25 | 0.4% | 1.8% | ||
| Q1 25 | 1.6% | 1.2% | ||
| Q4 24 | 6.7% | 5.1% | ||
| Q3 24 | 4.8% | 1.3% | ||
| Q2 24 | 0.5% | 2.1% | ||
| Q1 24 | 0.4% | 3.6% |
现金转化率CETXRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.33× | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | -0.43× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CETX
| Industrial Services | $10.6M | 66% |
| Security | $5.5M | 34% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
